Therefore, to evaluate the role of ALDH1A1 as a prognostic and predictive marker for tumour progression and response to chemotherapy in pancreatic cancer, standarised prospective studies with a larger number of patients are required. This evidence concerns the gene ALDH1A1 and familial pancreatic carcinoma.